The research progress of PD-1 channel inhibition in tumor treatment

doi:10.11958/j.issn.0253-9896.2015.09.036

Abstract

Abstract: Abstract: Programmed death1 (PD-1) is mainly expressed on the surface of activated T cell. The combination between PD-1 and its legends PD-L1/PD-L2 activate downstream signaling pathways and negatively regulate T cell activation. Ab⁃ normal increase expression of PD-L1 on tumor cell surface mediates the tumor immune escape. Inhibition of PD-1 signaling pathway contributes to antitumor effect of T cells. The development of this pathway inhibitors has become a hot spot for tu⁃ mor immunotherapy. This article expounds the progress about antitumor effects mediated by PD-1 pathway inhibition from experiments in vivo or in vitro and clinical development of PD-1 pathway inhibitors, providing a new target for cancer immu⁃ notherapy and theoretical and clinical basis for the clinical application of immunotherapy with traditional therapy methods.

Key words: neoplasms, immunotherapy, review, programmed death 1, PD-1 ligand

References

1. Pardoll, DM.The blockade of immune checkpoints in cancer immunotherapy[J].Nat Rev Cancer .2012;12(4) 252–264. 2. Boussiotis VA, Chatterjee P, Li L. Biochemical signaling of PD-1 on T cells and its functional implications[J].Cancer J.2014;20(4):265-71. 3. Jadus MR, Natividad J, Mai A,et al. Lung cancer: a classic example of tumor escape and progression while providing opportunities for immunological intervention[J].Clin Dev Immunol. 2012;2012: 160724. 4. Benson DM Jr, Bakan CE, Mishra A, et al. The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody[J]. Blood.2010;116(13): 2286–2294. 5. Merelli B, Massi D, Cattaneo L, et al. Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities[J]. Crit Rev Oncol Hematol.2014;89(1):140-65. 6. Baral A, Ye HX, Jiang PC, et al. B7-H3 and B7-H1 expression in cerebral spinal fluid and tumor tissue correlates with the malignancy grade of glioma patient[J].Oncol Lett.2014;8(3):1195-1201. 7. Lu B, Chen L, Zhu Y, et al. T-cell-mediated tumor immune surveillance and expression of B7 co-inhibitory molecules in cancers of the upper gastrointestinal tract[J].Immunol Res. 2011;50(2-3):269-75. 8. Rozali EN, Hato SV, Robinson BW, et al. Programmed death ligand 2 in cancer-induced immune suppression[J]. Clin Dev Immunol.2012;2012: 656340. 9. Chen L, Deng H, Lu M, et al.B7-H1 expression associates with tumor invasion and predicts patient’s survival in human esophageal cancer[J]. Int J Clin Exp Pathol.2014;7(9):6015-23. 10. Zhang Y, Huang S, Gong D, et al. Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer[J].Cell Mol Immunol. 2010;7(5):389-95. 11. McGee HS, Yaqita H, Shao Z, et al. Programmed Death-1 antibody blocks therapeutic effect of T-regulatory cells in cockroach antigen-induced allergic asthma[J].Am J Respir Cell Mol Biol.2010;43(4):432-42. 12. Spranger S, Koblish HK, Horton B, et al. Mechanism of tumor rejection with doublets of CTLA-4,PD-1/PD-L1,or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment[J]. J Immunother Cancer. 2014;2:3. 13.McDermott DF, Atkins MB. PD-1 as a potential target in cancer therapy[J]. Cancer Med. 2013;2(5):662-73. 14. Jaikumar Duraiswamy, Karen M, Kaluza, et al. Dual Blockade of PD-1 and CTLA-4 Combined with Tumor Vaccine Effectively Restores T Cell Rejection Function in Tumors[J]. Cancer Res.2013;73(12):3591-3603. 15. West EE, Jin HT, Rasheed AU, et al. PD-L1 blockade synergizes with IL-2 therapy in reinvigorating exhausted T cells[J]. J Clin Invest.2013;123(6):2604-15. 16.Mkrtichyan M, Chong N, Abu Eid R, et al. Anti-PD-1 antibody significantly increase therapeutic efficacy of Listeria monocytogenes(Lm)-LLO immunotherapy[J].J Immunother Cancer.2013;1:15. 17.Kono K. Current status of cancer immunotherpy[J]. J Stem Cels Regen Med.2014;10(1):8-13. 18. Mangsbo SM, Sandin LC, Anger K, et al. Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy[J].J Immunother. 2010;33(3): 225–235. 19. Wang S, Wang Y, Liu J, et al. Sliencing B7-H1 enhances the anti-tumor effect of bladder cancer antigen-loaded dendritic cell vaccine in vitro[J].Onco Targets Ther. 2014;7:1389-96. 20. Maekawa N, Konnai S, Ikebuchi R, et al.Expression of PD-L1 on canine tumor cells and enhancement of INF-γproduction from tumor-infiltrating cells by PD-L1 blockade[J]. PLoS One.2014;9(6):e98415. 21. Rosenblatt J, Glotabecker B, Mills H, et al. PD-1 blockade by CT-011, anti-PD-1 antibody, enhances ex vivo T-cell responses to autologous dendritic cell/myeloma fusion vaccine[J].J Immunother. 2011;34(5):409-18. 22. Han L, Liu F, Li R, et al. Role of programmed death ligands in effective T-cell interactions in extranodal natural killer/T-cell lymphoma[J]. Oncol Lett.2014;8(4):1461-1469. 23. Sznol M. Blockade of B7-H1/PD1 pathway as a basis for combination anticancer therapy[J]. Cancer J. 2014;20(4):290-5. 24. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer[J]. N Engl J Med. 2012;366(26):2455-65. 25. Lu J1, Lee-Gabel L2, Nadeau MC2, et al. Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy[J]. J Oncol Pharm Pract. 2014 , 9. pii: 1078155214538087. 26. Al-Farsi A, Ellis PM. Treatment paradigms for patients with metastatic non-small cell lung cancer, squamous lung cancer: first, second, and third-lin[J]e. Front Oncol. 2014 Jun 27,4,157. 27. Langer CJ. Emerging Immunotherapies in the Treatment of Non-Small Cell Lung Cancer (NSCLC): The Role of Immune Checkpoint Inhibitors[J].. Am J Clin Oncol. 2014, 28. [Epub ahead of print] 28. Shih K, Arhenau HT, Infante JR. Clinical impact of checkpoint inhibitors as novel cancer therapies[J]. Drugs. 2014;74(17):1993-2013. 29. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma[J]. N Engl J Med. 2013;369(2):122-33. 30. Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma[J]. N Engl J Med. 2010;363(8):711-23. 31. Lina TT, Alzahrani S, Gonzalez J, et al. Immune evasion strategies used by Helicobacter pylori[J].World J Gastroenterol. 2014;20(36):12753-12766. 32. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer[J]. N Engl J Med.2012;366(26):2443-54. 33. Herbst RS, et al. A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors[J]. J Clin Oncol.2013; 31:3000. 34. Christensen H, Hermann M. Immunological response as a source to variability in drug metabolism and transport. Front. Pharmacol[J]. 2012;3:8. 35. Evers R, Dallas S, Dickmann LJ, et al. Critical review of preclinical approaches to investigate cytochrome p450-mediated therapeutic protein drug-drug interactions and recommendations for best practices: a white paper[J]. Drug Metab Dispos. 2013;41(9):1598-609. 36. Lee JI, Zhang L, Men A.Y, et al.CYP-mediated therapeutic protein-drug interactions: clinical findings, proposed mechanisms and regulatory implications[J]. Clin Pharmacokinet. 2010;49(5):295-310.

[1]	ZHANG Jinwei, WANG Yan, WANG Tong. Effects of miR-107 on proliferation, invasion and migration of CAL27 cells in oral squamous cell carcinoma [J]. Tianjin Medical Journal, 2024, 52(9): 897-899.
[2]	WANG Yuanzhen, WEI Hongyan, CHANG Lixian, ZHANG Yingyuan, LIU Chunyun, LIU Li. Establishment and validation of a risk prediction model for primary liver cancer complicated with pulmonary infection before intervention [J]. Tianjin Medical Journal, 2024, 52(9): 940-945.
[3]	ZHANG Zhihua, CHANG Taihao, LUO Fei, WANG Yashen, LI Jian. Efficacy and safety of simultaneous prostate biopsy combined with PVP in the treatment of elderly, high-risk and suspected prostate cancer patients [J]. Tianjin Medical Journal, 2024, 52(9): 959-962.
[4]	WANG Xinbo, LUO Bingqing, SHI Yubao, ZHANG Ye, XI Jiangwei. Expression of LncRNA LINC00342 and miR-203a-3p in colorectal cancer tissue and their relationship with prognosis [J]. Tianjin Medical Journal, 2024, 52(9): 971-976.
[5]	DING Peisen, LIU Siyu, XING Zhilei, YU Xiaomeng, SONG Jiahui, CUI Yushan, LIU Hongliang. Visual analysis of molecular and cellular biology of thyroid cancer based on VOSviewer [J]. Tianjin Medical Journal, 2024, 52(9): 985-990.
[6]	GUO Zhenjiang, ZHAO Guangyuan, DU Liqiang, LIU Fangzhen. Development and validation of a preoperative nomogram predictive model for proximal gastric cancer with microscopic positive margin [J]. Tianjin Medical Journal, 2024, 52(8): 845-849.
[7]	MAN Yi, XU Ya, HE Xiancheng, SONG Shaofeng, LIU Aiguo. Relationship between expression levels of EGFR, Ki-67, P53 and CTC and the prognosis of triple negative breast cancer [J]. Tianjin Medical Journal, 2024, 52(8): 862-867.
[8]	ZHANG Guohua, ZHANG Lingling, GAO Lan, LUO Junli, SHEN Yawen, LIU Lei, WANG Yuhua. Clinical analysis of 16 cases of connective tissue disease-associated interstitial lung disease complicated with lung cancer [J]. Tianjin Medical Journal, 2024, 52(7): 687-690.
[9]	LIU Zhichao, LI Xiaohe, ZHOU Honggang, ZHANG Na. Overview of animal models of idiopathic inflammatory myopathy-associated interstitial lung disease [J]. Tianjin Medical Journal, 2024, 52(7): 709-713.
[10]	WU Jing, FAN Zhijuan, LIU Shuye. Changes and clinical significance of plasma free amino acid levels in the development of chronic hepatitis B to hepatocellular carcinoma [J]. Tianjin Medical Journal, 2024, 52(7): 738-742.
[11]	ZHU Gangming, DONG Yongde, ZHU Ruiting, TAN Yuanman, TAO Juan, LIU Xiao, CHEN Decheng, YANG Gai. The value of magnetic resonance relaxation time quantitative imaging in predicting molecular subtypes of invasive ductal carcinoma [J]. Tianjin Medical Journal, 2024, 52(7): 770-774.
[12]	XIE Wenfu, WEI Mingyong, ZHANG Shan, LIU Haiying, LEI Hao, ZOU Fangyuan. Comparative study of therapeutic effect of rubber ring and dental floss combined with hemoclipping assisted endoscopic submucosal dissection on early gastrointestinal tumor [J]. Tianjin Medical Journal, 2024, 52(6): 599-603.
[13]	HUO Jingchen, WANG Yue, LI Hua, QIU Rong, SU Jingwei, WANG Zhuofan, YANG Jie. Predictive value of systemic immune inflammation index (SII) on long-term survival of patients with stage III squamous lung cancer treated with radical radiotherapy [J]. Tianjin Medical Journal, 2024, 52(6): 634-638.
[14]	GU Cheng, SHEN Xinyu, SUN Jinghua, YAN Saike, WANG Haiping. The evaluation value of dynamic MRI imaging technology for LARS after anorectal preservation surgery in low rectal cancer [J]. Tianjin Medical Journal, 2024, 52(6): 653-657.
[15]	LIU Xiaoyan, BU Rui, LU Jianfei, DING Yu, ZHANG Xing. Value of Sonazoid contrast-enhanced ultrasound for preoperatively evaluating pathological grade of hepatocellular carcinoma [J]. Tianjin Medical Journal, 2024, 52(6): 658-662.